ERBB2 and gastric cancer: As summarized in Table 1, HER-2 serves as a critical predictive and prognostic biomarker in breast and gastric cancer, while emerging evidence supports its role in colorectal, endometrial, biliary tract, salivary gland, lung, and urothelial cancers.